Results 1 to 10 of about 244,204 (304)

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study [PDF]

Scientific Reports
During severe and critical COVID-19, therapeutic options remain scarce. Among interventions, the use of interleukin-6 receptor inhibitor (IL-6Ri) is especially controversial due to persistent uncertainty about their efficacy and safety.
Charlène Lefèvre, Théo Funck-Brentano, Marine Cachanado, Alexia Plocque, Maëlle Youinou, Audrey Fels, Frédéric Pène, Laurent Savale, David Montani, Olivier Voisin, Flore Bintein, Lucille Wildenberg, Axel Philippe, Stéphane Legriel, Nicolas Roche, Pierre-Régis Burgel, Marc Tran, Nicolas Noël, Christophe Baillard, Jacques Duranteau, Gilles Chatellier, Francois Philippart   +21 more
doaj   +6 more sources

Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors [PDF]

Clinical and Experimental Dental Research, 2015
AbstractInterleukin‐6 (IL‐6) may play a pathological role in rheumatoid arthritis (RA) and periodontitis. Although the efficacy of medication with IL‐6 receptor inhibitor, tocilizumab (TCZ), has been demonstrated in the treatment of RA, very little is known about whether TCZ therapy affects periodontitis.
Tetsuo Kobayashi, , Ichiei Narita
exaly   +4 more sources

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +2 more sources

IL-1Ra Protects Hepatocytes from CCl4-Induced Hepatocellular Apoptosis via Activating the ERK1/2 Pathway

Pharmaceutical Fronts, 2020
Interleukin-1 receptor antagonist is an important acute-phase protein and an immune mediator, and its expression is associated with the development of hepatitis or acute liver failure.
Ying Zheng, Xinyi Xiao, Zhuoyi Yang, Meiqi Zhou, Hui Chen, Siyi Bai, Jianwei Zhu, Yunsheng Yuan   +7 more
doaj   +1 more source

Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report)

Zaporožskij Medicinskij Žurnal, 2021
The aim is to familiarize practitioners with the clinical case of tocilizumab use in the combination treatment of the coronavirus disease (COVID-19) patient with concomitant rheumatoid arthritis. Materials and methods.
V. A. Vizir, A. S. Sadomov, O. V. Demidenko   +2 more
doaj   +1 more source

Dasatinib for treatment of CAR T-cell therapy-related complications

Journal for ImmunoTherapy of Cancer, 2022
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by ...
Jakob R Passweg, Dominik Heim, Katharina Baur, Astrid Beerlage, Anna S Poerings, Bastian Kopp, Michael Medinger, Jan C Dirks, Andreas Holbro   +8 more
doaj   +1 more source

Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Leukemia Research Reports, 2020
Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy.
Megan Melody, Emily Butts, David Menke, Kevin Landolfo, Keith Oken, Taimur Sher, Sharad Khurana   +6 more
doaj   +1 more source

Psoriatic arthritis successfully treated with second-line anti-interleukin-6 treatment: a case report and review of the literature 

Journal of Medical Case Reports, 2022
Background Psoriatic arthritis treatment with antitumor necrosis factor has been shown to reduce disease activity. Nonetheless, more than 30% of patients do not achieve a sufficient response to tumor necrosis factor blockers.
Tatsuhiko Kutsuna, Kazunori Hino, Hitoshi Hasegawa, Kunihiko Watamori, Teruki Kidani, Hiroshi Imai, Hiromasa Miura   +6 more
doaj   +1 more source

Effect of IRAK1/4 inhibitor on IL-1β, IL-6, INF-γ and TNF-α expression in breast cancer cells of several lines [PDF]

The Ukrainian Biochemical Journal, 2021
Recent studies have shown that inflammation mediated via interleukin-1 receptor-associated kinases (IRAKs) is associated with cancer cells drug resistance.
M. Rezaei, B. Shahouzehi, S. Rahemi, H. Fallah, M. Salarkarimi   +4 more
doaj   +1 more source

Contribution of Extracellular Signal-Regulated Kinase to UTP-Induced Interleukin-6 Biosynthesis in HaCaT Keratinocytes

Journal of Pharmacological Sciences, 2006
UTP causes interleukin (IL)-6 production via mRNA expression through P2Y2/P2Y4 receptors in human HaCaT keratinocytes. In the present study, we analyzed the mechanism of UTP-induced IL-6 production in these cells.
Daisaku Kobayashi, Satoko Ohkubo, Norimichi Nakahata   +2 more
doaj   +1 more source